GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » RaySearch Laboratories AB (OSTO:RAY B) » Definitions » Debt-to-EBITDA

RaySearch Laboratories AB (OSTO:RAY B) Debt-to-EBITDA : 2.87 (As of Mar. 2024)


View and export this data going back to 1991. Start your Free Trial

What is RaySearch Laboratories AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

RaySearch Laboratories AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr95 Mil. RaySearch Laboratories AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr430 Mil. RaySearch Laboratories AB's annualized EBITDA for the quarter that ended in Mar. 2024 was kr183 Mil. RaySearch Laboratories AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 2.87.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for RaySearch Laboratories AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:RAY B' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.23   Med: 0.66   Max: 3.7
Current: 3.7

During the past 13 years, the highest Debt-to-EBITDA Ratio of RaySearch Laboratories AB was 3.70. The lowest was 0.23. And the median was 0.66.

OSTO:RAY B's Debt-to-EBITDA is ranked worse than
64.73% of 431 companies
in the Healthcare Providers & Services industry
Industry Median: 2.55 vs OSTO:RAY B: 3.70

RaySearch Laboratories AB Debt-to-EBITDA Historical Data

The historical data trend for RaySearch Laboratories AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RaySearch Laboratories AB Debt-to-EBITDA Chart

RaySearch Laboratories AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.69 2.85 1.63 1.30

RaySearch Laboratories AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.70 7.19 4.42 2.69 2.87

Competitive Comparison of RaySearch Laboratories AB's Debt-to-EBITDA

For the Health Information Services subindustry, RaySearch Laboratories AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RaySearch Laboratories AB's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where RaySearch Laboratories AB's Debt-to-EBITDA falls into.



RaySearch Laboratories AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

RaySearch Laboratories AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(97.381 + 431.977) / 405.929
=1.30

RaySearch Laboratories AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(95.344 + 430.196) / 183.072
=2.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


RaySearch Laboratories AB  (OSTO:RAY B) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


RaySearch Laboratories AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of RaySearch Laboratories AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


RaySearch Laboratories AB (OSTO:RAY B) Business Description

Traded in Other Exchanges
Address
Sveavagen 44, P.O. Box 3297, Stockholm, SWE, 103 65
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops advanced software solutions for improved cancer treatment. The company develops and markets the RayStation* treatment planning system and RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of Sweden, North America, Asia, Europe and the rest of the world. The company generates majority of its sales from the North America.

RaySearch Laboratories AB (OSTO:RAY B) Headlines

No Headlines